Lymphoma Therapeutics: Market Research Report

April 2010 | 752 pages | ID: L475D36FA49EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Lymphoma Therapeutics in US$ Million.

The report provides separate comprehensive analytics for US, Europe, and Rest of World.

Annual estimates and forecasts are provided for each region for the period 2006 through 2015.

The report profiles 93 companies including many key and niche players such as Allos Therapeutics, Inc., Astellas Pharma US, Inc., Biogen Idec, Biolex Therapeutics, Inc., Biovest International, Inc., Cell Therapeutics, Inc, Cephalon, Inc., Chugai Pharmaceutical Co., Ltd., Cyclacel Pharmaceuticals, Inc., Eisai, Ltd., EpiCept Corp., F.Hoffmann-la Roche Ltd., Genentech, Inc., Genmab, Genitope Corp., Genzyme Corporation, GlaxoSmithKline, Plc, Hana Biosciences, Inc., ImmunoGen, Inc., InNexus Biotechnology, Inc., and Millennium Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Types of Lymphomas
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma

II. EXECUTIVE SUMMARY

1.GLOBAL OUTLOOK

Global Lymphoma Therapeutics Market to Surge
Europe Leads the Global Lymphoma Therapeutics Market
Lymphoma Incidence and Mortality Rates On the Rise
Incidence of Hodgkin's Lymphoma - High in West Asia

Table 1. Age-Standardized Incidence Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart)

Table 2. Age-Standardized Mortality Rates for Hodgkin’s Lymphoma in Select Countries Worldwide (2002) (includes corresponding Graph/Chart)

Rituxan’s Dominance - A Major Hurdle to Other Emerging Drugs
Huge Unmet Needs to Drive Product Innovation
Radioimmunotherapy Drug Penetration Continues to Remain Lower

Table 3. Monthly Cost of Select Non-Hodgkin’s Lymphoma Treatments (2009)

Sales of Zevalin to Gain Momentum
Combination Drugs – A Potential Winning Option for Manufacturers
Existing Drugs for Lymphoma
Select Approved Drugs In Lymphoma Treatment
Rituxan – the Undisputed Leader in NHL Drugs
Key Indications for Rituxan in the US
Zevalin (Biogen Idec)
Overview
Administration
Efficacy
Bexxar (GlaxoSmithKline)
Ribomustin®/Treanda®
Pipeline Drugs for Lymphoma
Select Pipeline Drugs In Lymphoma Treatment
Select Vaccines In Pipeline for Lymphoma Treatment
Pixantrone (Cell Therapeutics)
Affinitor (Novartis)
SGN-35 (Seattle Genetics)
SAR3419 (ImmunoGen, Inc.)
Overview of Treatment Options for NHL
Chemotherapy
Radiotherapy
Antibody Therapy
Stem Cell Transplants

2.PRODUCT OVERVIEW

Lymphomas
Types of Lymphomas
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
Classification – Based on Type of Cells Involved
Hodgkin’s Lymphomas
Natural Killer (NK) and Mature T cell Neoplasms
Mature B cell Neoplasms
Classification - Based on Disease Progression
Indolent Lymphomas
Aggressive Lymphomas
Background
Signs and Symptoms
Etiology and Risk Factors
Immunological functions
Infections
Lifestyle Factors
Diagnosis of Lymphoma
Prognosis
Treatment of Lymphoma

3.DRUG APPROVALS

Gloucester Obtains FDA Clearance for Istodax® in Treating CTCL
Allos Obtains FDA Approval for FOLOTYN™
Spectrum Receives FDA Approval for Zevalin® Expanded Label
Genzyme Receives European Commission Approval for Mozobil®
Cephalon Obtains FDA Approval for TREANDA for Treating Indolent NHL
GSK Receives European Approval for Atriance®

4.RECENT INDUSTRY ACTIVITY

Celgene to Acquire Gloucester Pharmaceuticals
Scientists at Cornell Discover New Molecular Mechanism for Treating NHL
CTI Seeks Orphan Drug Designation for Pixantrone in Europe
FDA's ODAC Recommends Romidepsin’s Approval
Seattle Genetics Completes Enrollment for Brentuximab Vedotin
InNexus Biotechnology to Initiate Business Development for DXL625
Allos Therapeutics Introduces focusonptcl.com
InNexus Inks Letter of Intent with Genhelix
Pfizer Acquires Wyeth
LLS and FORMA Join Hands to Accelerate Development of New Therapies
Biovest and idis Ink Partnership Deal for Distribution of BiovaxID®
SymBio Pharmaceuticals Signs a License Agreement with Eisai
Seattle Genetics Receives Fast Track Designation from FDA for SGN-35
Spectrum Acquires ZEVALIN® from RIT Oncology
EpiCept Announces Crinobulin as Generic Name for EPC2407
CTI Enters Into a Joint Venture with Spectrum Pharmaceuticals
Allos Receives Orphan Drug Designation for Pralatrexate from FDA
Takeda Acquires Millennium Pharmaceuticals

5.FOCUS ON SELECT GLOBAL PLAYERS

Allos Therapeutics, Inc. (US)
Astellas Pharma US, Inc. (US)
Biogen Idec (US)
Biolex Therapeutics, Inc. (US)
Biovest International, Inc. (US)
Cell Therapeutics, Inc. (US)
Cephalon, Inc. (US)
Chugai Pharmaceutical Co., Ltd. (Japan)
Cyclacel Pharmaceuticals, Inc. (US)
Eisai, Ltd. (Japan)
EpiCept Corp. (US)
F. Hoffmann-la Roche Ltd. (Switzerland)
Genentech, Inc. (US)
Genmab (Denmark)
Genitope Corp. (US)
Genzyme Corporation (US)
GlaxoSmithKline, Plc. (UK)
Hana Biosciences, Inc. (US)
ImmunoGen, Inc. (US)
InNexus Biotechnology, Inc. (Canada)
Millennium Pharmaceuticals, Inc. (US)

6.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Lymphoma Drugs Market by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

Table 5. World 10-year Perspective for Lymphoma Drugs Market by Geographic Region – Percentage Breakdown of Value Sales for US, Europe and Rest of World Markets for Years 2006, 2009 & 2015 (includes corresponding Graph/Chart)

III. MARKET

1.UNITED STATES

A. MARKET ANALYSIS

Rising Incidence of Lymphomas to Fuel Market Growth
Mortality Rate Slips
Lymphomas – The Third Leading Cause of Cancer in Children

Table 6. Percentage Breakdown of Cancer Incidence in US Children by Type (2006) (includes corresponding Graph/Chart)

White Children – Most Susceptible to Lymphomas

Table 7. Incidence of Lymphoma in US Children in 2006 (includes corresponding Graph/Chart)

Lymphoma Fact Sheet
Incidence Rate Rises in Afro-Americans

Table 8. US Lymphoma Incidence Rates in Men of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart)

Table 9. US Lymphoma Incidence Rates in Women of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart)

Table 10. US Lymphoma Mortality Rates in Men of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart)

Table 11. US Lymphoma Mortality Rates in Women of All Ages by Race: 2002-2006 (includes corresponding Graph/Chart)

Select Players in the Region
New Drug Approvals
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 12. US Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

2.EUROPE

A. MARKET ANALYSIS

Europe – The Largest Market for Lymphoma Therapeutics Worldwide
Incidence of NHL Continues to Climb

Table 13. Annual Incidence of Non-Hodgkin’s Lymphomas in Europe: 2003-2010 (includes corresponding Graph/Chart)

Table 14. Incidence Rates of Key Types of Non-Hodgkin’s Lymphomas in Europe:2006 (includes corresponding Graph/Chart)

Immunotherapeutic Drugs Dominate the Market
New Drugs to Transform Non-Hodgkin's Lymphoma Market
Restraining Forces Loom Large Over New Drugs
An Overview of Lymphomas in United Kingdom

Table 15. Hodgkin’s Lymphoma Incidence in UK (2006)

Table 16. Hodgkin’s Lymphoma Incidence in UK by Sex (2006): Percentage Breakdown by Age Group (includes corresponding Graph/Chart)

Select Players in the Region
New Drug Approvals
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 17. European Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

3.REST OF WORLD

A. MARKET ANALYSIS

Rest of World Lymphoma Therapeutics Market to Witness Rapid Growth
Select Players in the Region
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 18. Rest of World Recent Past, Current & Future Analysis for Lymphoma Drugs Market with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 93 (including Divisions/Subsidiaries - 104)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)